Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05461378 · ClinicalTrials.gov registry record
PREP (Pre-Exposure Prophylaxis) of COVID-19
A clinical trial of COVID-19 and Immunodeficiency, sponsored by Ghady Haidar.
- Completed
- Registry status
- 138
- Enrollment target
- 1
- Study location
NCT05461378: Completed study of COVID-19 and Immunodeficiency, sponsored by Ghady Haidar.
NCT05461378 is a study of COVID-19 and Immunodeficiency that has completed, run by Ghady Haidar. The registered enrollment target is 138 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05461378, a study of COVID-19 and Immunodeficiency, has completed, sponsored by Ghady Haidar.
- COMPLETED
- Registry status
- 138 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study of immunocompromised individuals who have received or plan to receive a drug called EVUSHELD. This study is looking at any serious adverse events that might happen after receiving EVUSHELD, the levels of EVUSHELD in participant's blood, blood antibody levels, neutralizing antibodies against SARS-CoV-2 (the virus that causes COVID-19), and other blood responses related to the immune system and COVID-19. Investigators are collecting blood and may also collect other samples such as nose swabs, oral swabs, or saliva.
Primary Outcome
The primary objective of PrEP C-19 is to measure AZD7442 serum concentration levels by blood draws at 6 months (or at enrollment if the time point has passed) and 12 months after IM administration of EVUSHELD.
Conditions Studied
Interventions
- DRUG Evusheld
Study Locations (1)
Pennsylvania
- UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2022-07-26 |
| Est. Completion | 2024-01-29 |
What the finished NCT05461378 record still lists
NCT05461378 is an observational study that tracks outcomes without assigning an intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Evusheld is the first listed.
NCT05461378 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05461378 about?
NCT05461378 is a clinical study titled "PREP (Pre-Exposure Prophylaxis) of COVID-19". This is a study of immunocompromised individuals who have received or plan to receive a drug called EVUSHELD. This study is looking at any serious adverse events that might happen after receiving EVUSHELD, the levels of EVUSHELD in participant's blood, blood antibody levels, neutralizing antibodies ...
What is the current status of trial NCT05461378?
This trial is currently completed. The enrollment target is 138 participants. The study started on 2022-07-26. Estimated completion is 2024-01-29.
What conditions does trial NCT05461378 study?
This clinical trial studies the following conditions: COVID-19, Immunodeficiency.
What interventions are being tested in trial NCT05461378?
The interventions under investigation include: Evusheld (DRUG).
Who is sponsoring clinical trial NCT05461378?
This trial is sponsored by Ghady Haidar, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05461378 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05461378's enrollment target sits among peer trials
138 183rd of 298 higher than 116 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI